Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Noxopharm Ltd. ( (AU:NOX) ) is now available.
Noxopharm Limited has notified the market of the issue of 520,000 unquoted options, exercisable at A$0.1488 and expiring on 10 September 2027, along with 2.6 million unquoted convertible notes, both dated 2 January 2026. The new options and convertible notes expand the company’s pool of unquoted securities and indicate continued use of structured equity and hybrid instruments to support its financing needs, with potential future dilution and capital structure changes relevant to existing shareholders and investors tracking the company’s funding strategy.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
More about Noxopharm Ltd.
Noxopharm Limited is an Australian-listed biotechnology company focused on developing therapeutics, with its shares traded on the ASX under the code NOX. The company typically funds its research and development activities through capital markets, including the issuance of various equity and debt-like securities.
Average Trading Volume: 65,930
Technical Sentiment Signal: Buy
Current Market Cap: A$28.93M
See more data about NOX stock on TipRanks’ Stock Analysis page.